Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Breast conservation after neoadjuvant chemotherapy.

Allen M Chen1, Funda Meric-Bernstam, Kelly K Hunt

  • 1Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.

Cancer
|January 11, 2005
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Access Improvement in Healthcare: Be Quick, but Don't Hurry?

Learning health systems·2026
Same author

Advances in Targeting HER2 across Cancer Subtypes: A Pan-Tumor Approach.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025
Same author

Stepwise disassembly of supramolecular structures triggered by specific protein binding.

Biophysical journal·2025
Same author

Re-Evaluating Access in Healthcare: Focus on Quality of Care.

Public health challenges·2025
Same author

Evidence-based framework for the management of disruptive physician behavior.

Journal of healthcare risk management : the journal of the American Society for Healthcare Risk Management·2025
Same author

Epidemiological Trends in the Characterization of Human Papillomavirus Virus-Related Oropharyngeal Cancer: A Global Perspective.

Current oncology reports·2025

This study developed the M. D. Anderson Prognostic Index (MDAPI) to guide breast-conserving therapy (BCT) selection after neoadjuvant chemotherapy. The MDAPI effectively stratifies patients, identifying those at low or high risk for recurrence.

Area of Science:

  • Oncology
  • Surgical Oncology
  • Breast Cancer Research

Background:

  • Selection criteria for breast-conserving therapy (BCT) following neoadjuvant chemotherapy require refinement.
  • Current decision-making for this multimodality approach lacks a standardized prognostic framework.

Purpose of the Study:

  • To develop a prognostic index to improve selection criteria for BCT after neoadjuvant chemotherapy.
  • To establish a framework for clinical decision-making in patients undergoing neoadjuvant chemotherapy and BCT.

Main Methods:

  • Utilized data from 340 patients treated with BCT post-neoadjuvant chemotherapy.
  • Identified four significant predictors of ipsilateral breast tumor recurrence (IBTR) and locoregional recurrence (LRR): clinical N2/N3 disease, residual tumor size >2 cm, multifocal disease, and lymphovascular invasion.

Related Experiment Videos

  • Developed the M. D. Anderson Prognostic Index (MDAPI) by assigning scores (0 or 1) to each predictor, resulting in a total score of 0-4.

    • Main Results:

    • The MDAPI stratified patients into low (score 0-1), intermediate (score 2), and high (score 3-4) risk groups for IBTR and LRR.
    • Five-year IBTR-free survival rates were 97% (low), 88% (intermediate), and 82% (high risk).
    • Five-year LRR-free survival rates were 94% (low), 83% (intermediate), and 58% (high risk).

    Conclusions:

    • MDAPI scores of 0 or 1 (81% of patients) indicated very low rates of IBTR and LRR.
    • The MDAPI identified a high-risk group (4% of patients) who may benefit from alternative locoregional treatments.
    • The MDAPI serves as a valuable tool for refining BCT selection and guiding treatment decisions.